Mikko Mannerkoski, MSc (Tech), MBA

Mikko Mannerkoski is the Chairman of the Board of Aranda. Mikko brings Aranda over 20 years of experience in helping create and execute on value-creation strategies. He initially worked in investment banking advising major corporate and private equity clients in mergers & acquisitions and capital market transactions. He rose to a leadership position in what was at the time a leading corporate finance advisory in Northern Europe before setting on an entrepreneurial track. For the past 10 years Mikko has been active in the life-science field as a founder and shareholder in a handful of companies in the US and in Finland that work in radiation oncology, immune-oncology, antibody-drug conjugates and diagnostics. Mikko has a M.Sc. from Helsinki University of Technology (currently Aalto University, Department of Bioproducts and Biosystems) and M.B.A. in finance from the Helsinki School of Economics with studies at the Ross School of Business of the University of Michigan. Currently Mikko is CFO at Rappta Therapeutics Ltd.

Erkki Tenhunen

Erkki Tenhunen is a Board member of Aranda. Erkki brings Aranda 25 years of expertise in high technology start-up companies, fundraising, business development and commercialization of drug development and MedTech projects. He started his career in life-sciences by co-founding Contral Pharma that developed a drug against alcoholism. The company was later listed on the Helsinki Stock Exchange subsequently sold to a US acquirer in a public tender offer. Erkki has later co-founded several companies developing radiation therapy equipment and anti-cancer pharmaceutical technologies. Currently Erkki is head of Business Development at Rappta Therapeutics Ltd.

Milla Koistinaho, PhD, Adjunct professor in Neurobiology

Milla Koistinaho is a founder and a Board member of Aranda.

Milla is a biotech commercialization professional with over 20 years of experience in commercializing early stage biomedical inventions. After completing her PhD thesis in Neurosciences in co-operation with Silicon Valley based biopharma company and gaining postgraduate experience with Eli Lilly and Company she has co-founded 3 biotech start ups based on her own academic discoveries. During the entrepreneurial years she has gained deep experience in pharmaceutical discovery and development, IPR generation and prosecution, fundraising, out-licensing and other corporate transactions. She has also served as the COO of technology transfer operations at the University of Helsinki being responsible for the identification of inventions, managing the University’s patent portfolio, licensing and spinning out companies arising from academic excellence. Milla Koistinaho is a founding partner of a new 90m EUR venture capital fund, Innovestor Life Science, investing in Seed to Series A stage, strong health sciences based companies in the Nordics and Baltics. Milla also holds several non-executive directorships in therapeutics development companies in the Nordics and serves as a member of the commercialization advisory board of University of Helsinki.